Trial Profile
A Phase II Exploratory Study of Pre-Operative Treatment with Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Bladder cancer; Ureteral neoplasms; Urogenital cancer
- Focus Therapeutic Use
- 17 Dec 2019 Status changed from active, no longer recruiting to completed.
- 13 Sep 2018 Planned End Date changed from 1 Jun 2019 to 30 Jun 2019.
- 13 Sep 2018 Planned primary completion date changed from 1 Jun 2019 to 30 Jun 2019.